Research
Immunotargeting and Radiobiology in Oncology : A. Pèlegrin

publications

Latorzeff I, Sargos P, Créhange G, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]. Cancer Radiother. Feb 11, 2020. doi:10.1016/j.canrad.2019.06.018

Maria A, Bourgier C, Martinaud C, Borie R, Rozier P, Rivière S, Crestani B, Guilpain P [From fibrogenesis towards fibrosis: Pathophysiological mechanisms and clinical presentations]. Rev Med Interne. Feb 08, 2020. doi:10.1016/j.revmed.2020.01.002

Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud H-A, Chardès T, Tosi D, Pèlegrin A, Azria D, Larbouret C, Bourgier C Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. Int. J. Radiat. Oncol. Biol. Phys.. Jan 17, 2020. doi:10.1016/j.ijrobp.2019.12.020

Bosma S, Vd Leij F, Vreeswijk S, de Maaker M, Wesseling J, Vd Vijver M, Scholten A, Rivera S, Bourgier C, Auzac G, Foukakis T, Lekberg T, Vd Bongard D, Loo C, Rutgers E, Bartelink H, Elkhuizen P Five-year results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. Int. J. Radiat. Oncol. Biol. Phys.. Jan 24, 2020. doi:10.1016/j.ijrobp.2019.12.037

Latorzeff I, Bourgier C, Pinel B, Hennequin C, Jimenez G, Chapet O, Zasadny X [Treatment of primary disease (breast, non-small cell lung and prostate cancers) with irradiation in case of de novo metastatic cancer]. Cancer Radiother. Sep 06, 2019. doi:10.1016/j.canrad.2019.08.004

Bourgier C, Latorzeff I, Fenoglietto P, Boisselier P, Charissoux M, Llacer C, Lemanski C, Riou O, Farcy-Jacquet M-P, Azria D [Treatment of oligometastatic or oligoprogression cancer]. Cancer Radiother. Sep 05, 2019. doi:10.1016/j.canrad.2019.07.143

Barbet J, Le Gouill S, Pèlegrin A [Radioimmunotherapy: the reasons for confidential clinical use and hope for development]. Med Sci (Paris). 2019;35(12):1062-1065. doi:10.1051/medsci/2019206

Riou O, Bourgier C, Brengues M, Bonnefoi N, Michaud H-A, Castan F, Gourgou S, Draghici R, Farcy-Jacquet M-P, Bons F, Fenoglietto P, Ozsahin M, Azria D [Predictive assays for responses of tumors and normal tissues in radiation oncology]. Cancer Radiother. Aug 23, 2019. doi:10.1016/j.canrad.2019.07.152

Larivière M, Pèlegrin A, Martineau P, Watier H [Players from the program "Investments for the Future": MAbImprove MabEx]. Med Sci (Paris). 2019;35(12):1204-1205. doi:10.1051/medsci/2019249

Larbouret C, Poul M-A, Chardès T [Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures]. Med Sci (Paris). 2019;35(12):1083-1091. doi:10.1051/medsci/2019216

Riou O, Valdenaire S, Debuire P, Fenoglietto P, Debrigode C, Mazard T, Assenat É, Azria D [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?]. Cancer Radiother. Aug 20, 2019. doi:10.1016/j.canrad.2019.07.159

Bourgier C, Lemanski C, Draghici R, Castan F, Fenoglietto P, Bons F, Farcy-Jacquet M-P, Brengues M, Gourgou S, Ozsahin M, Azria D [Individual modification of the dose, volume and fractionation of breast radiotherapy]. Cancer Radiother. Aug 01, 2019. doi:10.1016/j.canrad.2019.06.004

Pèlegrin A, Gutowski M, Cailler F [Antibodies, tools of choice for fluorescence-guided surgery]. Med Sci (Paris). 2019;35(12):1066-1071. doi:10.1051/medsci/2019207

Pèlegrin A, Beck A, Watier H [A word from the coordinators]. Med Sci (Paris). 2019;35(12):923. doi:10.1051/medsci/2019245

Prunaretty J, Boisselier P, Riou O, Simeon S, Bedos L, Azria D, Fenoglietto P Tracking, gating, free-breathing, which technique to use for lung stereotactic treatments? A dosimetric comparison. Rep Pract Oncol Radiother. 2019;24(1):97-104. doi:10.1016/j.rpor.2018.11.003

Framery B, Gutowski M, Dumas K, Evrard A, Muller N, Dubois V, Quinonero J, Scherninski F, Pèlegrin A, Cailler F Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients. Toxicol Rep. 2019;6. doi:10.1016/j.toxrep.2019.04.011

Montero-Luis A, Aristei C, Meattini I, Arenas M, Boersma L, Bourgier C, Coles C, Cutuli B, Falcinelli L, Kaidar-Person O, Leonardi M, Offersen B, Marazzi F, Rivera S, Tagliaferri L, Tombolini V, Vidali C, Valentini V, Poortmans P The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. Crit. Rev. Oncol. Hematol.. 2019;138. doi:10.1016/j.critrevonc.2019.04.016

Martineau P, Watier H, Turtoi A Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France. MAbs. 2019;11(5):812-825. doi:10.1080/19420862.2019.1612691

Amestoy F, Roubaud G, Antoine M, Fonteyne V, Baumann B, Christodouleas J, Azria D, Zilli T, Hennequin C, Xylinas E, Sargos P Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Crit. Rev. Oncol. Hematol.. 2019;142. doi:10.1016/j.critrevonc.2019.06.010

Seibold P, Webb A, Aguado-Barrera M, Azria D, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning A, Elliott R, Farcy-Jacquet M-P, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson D, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein B, De Ruysscher D, De Santis M, Schäfer J, Schnabel T, Sperk E, Symonds R, Stobart H, Taboada-Valladares B, Talbot C, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West C, Chang-Claude J REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol. 2019;138. doi:10.1016/j.radonc.2019.04.034

Lacombe J, Brengues M, Mangé A, Bourgier C, Gourgou S, Pèlegrin A, Ozsahin M, Solassol J, Azria D Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity. Radiat Oncol. 2019;14(1):142. doi:10.1186/s13014-019-1351-8

Auperin A, Rivera S, Boisselier P, Lang P, Lassau N, Taourel P, Azria D, Bourhis J, Deutsch E, Vozenin M-C Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. Int. J. Radiat. Oncol. Biol. Phys.. 2019;104(2):365-373. doi:10.1016/j.ijrobp.2019.02.024

Talbot C, Veldwijk M, Azria D, Batini C, Bierbaum M, Brengues M, Chang-Claude J, Johnson K, Keller A, Smith S, Sperk E, Symonds R, Wenz F, West C, Herskind C Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity. Clin Transl Radiat Oncol. 2019;18. doi:10.1016/j.ctro.2019.06.001

Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R, Poul M-A, Barret J-M, Prost J-F, Pèlegrin A, Chardès T ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun. Signal. 2019;17(1):106. doi:10.1186/s12964-019-0413-8

Boige V, Mollevi C, Gourgou S, Azria D, Seitz J-F, Vincent M, Bigot L, Juzyna B, Miran I, Gerard J-P, Laurent-Puig P Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. Int. J. Cancer. 2019;145(11):3163-3172. doi:10.1002/ijc.32417



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés